RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial

被引：1
|
作者：
Johnson, M. L. [1 ]
Langdon, R. [2 ]
Ellison, D. [3 ]
Spira, A. [4 ]
Amin, H. [5 ]
Castine, M. [6 ]
Daniel, D. B. [7 ]
Sohoni, S. [8 ]
Chen, Y-C. [8 ]
Hayes, J. [8 ]
Mu, Y. [8 ]
Masciari, S. [9 ]
Wang, X. [8 ]
Toya, S. [10 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Nebraska Canc Specialists, Omaha, NE USA
[3] Charleston Oncol PA, Charleston, SC USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Boca Raton Clin Res Associates Inc, Plantation, FL USA
[6] Hematol Oncol Clin, Baton Rouge, LA USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Chattanooga, TN USA
[8] Revolut Med, Redwood City, CA USA
[9] Sanofi, Cambridge, MA USA
[10] GenHarp Clin Solut LLC, Evergreen Pk, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
76TiP
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation.
    Sommerhalder, David
    Thevathasan, Jeena
    Ianopulos, Xenophon
    Volinn, Weining
    Hong, David
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
    Xie, Lu
    Xu, Jie
    Sun, Xin
    Tang, Xiaodong
    Yan, Taiqiang
    Yang, Rongli
    Guo, Wei
    ONCOLOGIST, 2019, 24 (07): : E542 - E550
  • [23] Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R-H.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Shen, Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1662
  • [24] Phase II Trial of the C-Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy
    Paik, Paul
    Stammberger, Uz
    Bruns, Rolf
    Overton, Lindsay
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1230 - S1230
  • [25] A Single-Arm Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel Monotherapy After Standard Therapy for Advanced NSCLC
    Kato, Y.
    Okuma, Y.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S919 - S920
  • [26] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
    Hong, David S.
    Kuo, James
    Sacher, Adrian G.
    Barlesi, Fabrice
    Besse, Benjamin
    Kuboki, Yasutoshi
    Dy, Grace K.
    Dembla, Vikas
    Krauss, John C.
    Burns, Timothy F.
    Kim, June
    Henary, Haby
    Ngarmchamnanrith, Gataree
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial
    Janne, P. A.
    Reckamp, K.
    Koczywas, M.
    Engelman, J. A.
    Camidge, D. R.
    Rajan, A.
    Khuri, F.
    Liang, J. Q.
    O'Connell, J.
    Giaccone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial
    Xu, Jie
    Xie, Lu
    Sun, Xin
    Liu, Kuisheng
    Tang, Xiaodong
    Yan, Taiqiang
    Yang, Rongli
    Guo, Wei
    Gu, Jin
    ONCOLOGIST, 2021, 26 (07): : E1256 - E1262
  • [29] Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies
    Govindan, Ramaswamy
    Crowley, John
    Schwartzberg, Lee
    Kennedy, Peter
    Williams, Charles
    Ekstrand, Bradley
    Sandler, Alan
    Jaunakais, Dinah
    Bolejack, Vanessa
    Ghalie, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4848 - 4854
  • [30] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
    Fakih, M.
    Durm, G.
    Govindan, R.
    Falchook, G.
    Soman, N.
    Henary, H.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
12345